398 related articles for article (PubMed ID: 27860138)
1. A novel sample size formula for the weighted log-rank test under the proportional hazards cure model.
Xiong X; Wu J
Pharm Stat; 2017 Jan; 16(1):87-94. PubMed ID: 27860138
[TBL] [Abstract][Full Text] [Related]
2. Weighted log-rank test for time-to-event data in immunotherapy trials with random delayed treatment effect and cure rate.
Liu S; Chu C; Rong A
Pharm Stat; 2018 Sep; 17(5):541-554. PubMed ID: 30058101
[TBL] [Abstract][Full Text] [Related]
3. Sample size calculation for testing differences between cure rates with the optimal log-rank test.
Wu J
J Biopharm Stat; 2017; 27(1):124-134. PubMed ID: 26882262
[TBL] [Abstract][Full Text] [Related]
4. Sample size calculation for the proportional hazards cure model.
Wang S; Zhang J; Lu W
Stat Med; 2012 Dec; 31(29):3959-71. PubMed ID: 22786805
[TBL] [Abstract][Full Text] [Related]
5. A sample size formula for the supremum log-rank statistic.
Eng KH; Kosorok MR
Biometrics; 2005 Mar; 61(1):86-91. PubMed ID: 15737081
[TBL] [Abstract][Full Text] [Related]
6. Cancer immunotherapy trial design with cure rate and delayed treatment effect.
Wei J; Wu J
Stat Med; 2020 Mar; 39(6):698-708. PubMed ID: 31773770
[TBL] [Abstract][Full Text] [Related]
7. Cancer immunotherapy trial design with long-term survivors.
Ding X; Wu J
Pharm Stat; 2021 Jan; 20(1):117-128. PubMed ID: 32869945
[TBL] [Abstract][Full Text] [Related]
8. A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazards.
Tang Y
Stat Methods Med Res; 2021 May; 30(5):1211-1234. PubMed ID: 33819109
[TBL] [Abstract][Full Text] [Related]
9. Study design of single-arm phase II immunotherapy trials with long-term survivors and random delayed treatment effect.
Chu C; Liu S; Rong A
Pharm Stat; 2020 Jul; 19(4):358-369. PubMed ID: 31930622
[TBL] [Abstract][Full Text] [Related]
10. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
Eaton A; Therneau T; Le-Rademacher J
Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
[TBL] [Abstract][Full Text] [Related]
11. Cancer immunotherapy trial design with delayed treatment effect.
Wu J; Wei J
Pharm Stat; 2020 May; 19(3):202-213. PubMed ID: 31729149
[TBL] [Abstract][Full Text] [Related]
12. On sample size calculation for comparing survival curves under general hypothesis testing.
Jung SH; Chow SC
J Biopharm Stat; 2012; 22(3):485-95. PubMed ID: 22416836
[TBL] [Abstract][Full Text] [Related]
13. Sample size calculation for mixture model based on geometric average hazard ratio and its applications to nonproportional hazard.
Wang Z; Zhang Q; Xue A; Whitmore J
Pharm Stat; 2024; 23(3):325-338. PubMed ID: 38152873
[TBL] [Abstract][Full Text] [Related]
14. Cancer immunotherapy trial design with random delayed treatment effect and cure rate.
Wu J; Wei J
Stat Med; 2022 Feb; 41(4):786-797. PubMed ID: 34779534
[TBL] [Abstract][Full Text] [Related]
15. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
Horiguchi M; Hassett MJ; Uno H
Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
[TBL] [Abstract][Full Text] [Related]
16. Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice.
Jachno K; Heritier S; Wolfe R
BMC Med Res Methodol; 2019 May; 19(1):103. PubMed ID: 31096924
[TBL] [Abstract][Full Text] [Related]
17. Design considerations in clinical trials with cure rate survival data: A case study in oncology.
Sun S; Liu G; Lyu T; Xue F; Yeh TM; Rao S
Pharm Stat; 2018 Mar; 17(2):94-104. PubMed ID: 29159922
[TBL] [Abstract][Full Text] [Related]
18. Sample size re-estimation for survival data in clinical trials with an adaptive design.
Togo K; Iwasaki M
Pharm Stat; 2011; 10(4):325-31. PubMed ID: 22328325
[TBL] [Abstract][Full Text] [Related]
19. Single-Arm Phase II Survival Trial Design Under the Proportional Hazards Model.
Wu J
Stat Biopharm Res; 2017; 9(1):25-34. PubMed ID: 28966721
[TBL] [Abstract][Full Text] [Related]
20. Interim monitoring using the adaptively weighted log-rank test in clinical trials for survival outcomes.
Yang S
Stat Med; 2019 Feb; 38(4):601-612. PubMed ID: 30209818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
